Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as rIL-21, NN028
recombinant interleukin-21 · 3 trials · 4 indications
| Arm | Type | Description |
|---|---|---|
| A | EXPERIMENTAL | - |
| B | EXPERIMENTAL | - |
| C | EXPERIMENTAL | - |
| D | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| recombinant interleukin-21 | DRUG | Administered i.v. in treatment cycles of 28 days. |
| caelyx (pegylated liposomal doxorubicin) | DRUG | Administered i.v. in treatment cycles of 28 days. |
| sunitinib | DRUG | Hard gelatine capsules, 12.5 mg |
Inclusion Criteria: * Advanced epithelial Ovarian Cancer (stage IIB-IV) * Persistent or progressive disease after or relapse within one year of completion of first line therapy * Measurable or assessable disease * Eastern Cooperative Oncology Group status less than or equal to 2 Exclusion Criteria...
Top 2 of 4 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| GE Healthcare Technologies Inc. | GEHC | 1 | PHASE1 | GEH200520/GEH200521 |
| Ascentage Pharma Group International Unsponsored ADR | AAPG | 1 | PHASE1 | Olverembatinib |
Recombinant interleukin-21 is an investigational cancer therapy studied in several tumor types. Phase 2 trials have evaluated it in metastatic melanoma, ovarian cancer, and renal cell carcinoma, including a combination study with sunitinib in stage IV renal cell carcinoma. It is not approved and remains in clinical development.
Recombinant interleukin-21 is an exogenous protein designed to act on the F9 target. As a recombinant form of the cytokine interleukin-21, it is given as a therapeutic protein rather than a conventional small molecule drug. Its target class is classified as an exogenous protein in oncology development.
Recombinant interleukin-21 is being developed by Novo Nordisk A/S, which trades under the ticker NVO. The company is the sponsor behind the clinical program evaluating the agent in cancer indications.
Recombinant interleukin-21 is in Phase 2 development. All three of its recorded trials are Phase 2 studies, and all three are completed, with no active trials currently listed. It is an investigational agent and has not been approved for any indication.
Three completed Phase 2 trials have studied recombinant interleukin-21: NCT00617253 combined it with sunitinib in stage IV renal cell carcinoma, NCT00523380 evaluated it in ovarian cancer, and NCT00336986 tested it in metastatic melanoma. Together these trials enrolled 73 patients across Germany, the Netherlands, France, and Australia.